Johnson & Johnson (NYSE:JNJ) has released new financial results for previous quarters that strip out the consumer-health unit that was recently hived off into a new company called Kenvue.
J&J, which is now focused on its pharmaceutical and medical technology businesses, said second-quarter sales were $21.52 billion, up 6.5% from a year ago.
Last month, the company reported second-quarter sales of $25.53 billion, which included the consumer-health business.
“The completion of this transaction uniquely positions Johnson & Johnson (NYSE:JNJ) as a Pharmaceutical and MedTech company focused on delivering transformative healthcare solutions to patients,” said Joaquin Duato, chair and chief executive officer.
J&J also said that second-quarter adjusted earnings per share from continuing operations were $2.56 without the consumer-health business, down from the $2.80 a share that it reported last month.
The drug maker now expects full-year reported sales of $83.2 billion to $84.0 billion, down from previous guidance of $98.8 billion to $99.8 billion.
Sales growth of 7.0%-8.0% is predicted and adjusted reported EPS of $10.00-$10.10, compared to 6.5%-7.5% and $10.70-$10.80 before.